This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the adult population aged 18 to 59 years without prior exposure to either arbovirus.
Male or female adults aged 18 to 59 years at the time of vaccination.
Signed informed consent by the participant or their legal representatives.
Ability to understand, based on the investigator's assessment, and agree to comply with all study procedures, including blood collection.
Participation in another clinical trial within 28 days prior to screening or planned participation in another clinical study during the trial period.
Pre-existing unstable health condition. An unstable health condition is defined as a disease requiring a change in treatment or hospitalization due to disease worsening within 90 days prior to screening.
Vaccination within 14 days prior to screening with any inactivated vaccine or within 28 days prior to screening with any live attenuated vaccine, or planned vaccination with any vaccine up to 28 days after study vaccination.
Known hypersensitivity to any component of the vaccines.